Paper Survey

Survey to assess the feasibility of establishing a gynecologic specimen bank for research

• Would you consider your practice to be primarily:

  • academic (primary activity within medical school teaching hospital or research institute)

  • private laboratory (not at the hospital)

  • private hospital (not affiliated with a medical center or research institute)

  • laboratory affiliated with managed health organization

• What is the approximate annual surgical pathology specimen volume at the laboratory where you practice (if multiple, give largest):

  • <10K

  • 10-25K

  • >25-50K

  • >50K

• What proportion of these specimens are gynecologic?

  • <10%

  • 10-20%

  • >20-50%

  • >50-100%

• Does your laboratory have a subspecialty sign-out with a designated gynecologic section?

  • No

  • Yes

• Does your laboratory receive risk-reducing surgery specimens from women at high-risk for gynecologic disease/cancer? If so, estimate annual number?

  • No

  • Yes (annual number: ___)

How are specimens for the following specific indications processed?

Clinical Indication	SEE-Fim (Sectioning and Extensively Examining of the Fimbria)	Submit fimbria	Submit ovaries	Endometrium
High-Grade Serous Cancer Stage I, II, IIIAi	No Yes	No Yes (total) Yes (partial)	No Yes (total) Yes (partial)	No Yes (total) Yes (partial)
Risk-reducing salpingo-oophorectomy or salpingectomy	No Yes	No Yes (total) Yes (partial)	No Yes (total) Yes (partial)	No Yes (total) Yes (partial)
Surgery for benign indications, first sections reveal equivocal or definite STIC (serous tubal intraepithelial carcinoma), epithelial atypia in ovary or clinically occult cancer	No Yes	No Yes (total) Yes (partial)	No Yes (total) Yes (partial)	No Yes (total) Yes (partial)
Surgery for benign indications, first sections reviewed are negative	No Yes	No Yes (total) Yes (partial)	No Yes (total) Yes (partial)	No Yes (total) Yes (partial)

• Does your laboratory stain sections of fimbria for Ki67, p53 or other markers (check all that apply):

  • On every specimen?

  • On every risk-reducing salpingo-oophorectomy or salpingectomy specimen?

  • On selected risk-reducing salpingo-oophorectomy or salpingectomy specimens based on H&E review?

  • On early stage high-grade serous cancer?

  • Markers not evaluated

• Would your laboratory consider providing de-identified blocks and matched pathology reports to a national specimen bank organized by the National Cancer Institute (NCI) to provide access to researchers throughout the world? Possible specimens would include risk-reducing salpingo-oophorectomy or salpingectomy, early high-grade serous cancer (HGSC), serous tubal intraepithelial carcinoma (STIC), and a minor percentage (10%) of total benign tubes and ovaries.

  • No

  • Yes

• Other comments/clarifications?

2